P/B
1,6
Fate Therapeutics
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
$249.2M
Market Cap • 10/30/2026
2007
(19 years)
Founded
2013
(13 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
38,4
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,3
EPS
—
Market Cap
Market Cap
249,2M
EV
171,1M
EV/Revenue
26,4
EV/EBITDA
-1,4
EV/EBIT
-1,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-1,6B
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
1546%
Capex/Revenue
57,2%
Capex/D&A
31%
Capex/OCF
-3,6%
SBC/OCF
—
% PPE
35,4%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-33%
CAGR Op. Income 5Y
-3,3%
CAGR Net Income 5Y
-9,9%
CAGR EPS 5Y
-14,9%
CAGR OCF 5Y
-1,6%
Leverage
N.D./EBITDA
0,6
Debt/Equity
0%
Current Ratio
4,8
Quick Ratio
4,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!